Call us directly: +44 (0)7905 201857

Email us info@sehta.co.uk

Members log in

Nov 28

SEHTA PR: SEHTA & Beamline Diagnostics

SEHTA is proud to announce its partnership with Beamline Diagnostics who have been awarded a phase two contract of £700k funding from the latest SBRI Healthcare call aimed at exploring the expansion of the BeamLine screening system to colon cancer. This will allow Beamline Diagnostics to carry out a proof-of-concept 200 patient trial and bring the colon cancer work up to the same level as their existing oesophageal cancer screening product. The primary role for SEHTA will be to help Beamline understand and develop a commercialisation plan for their product.

To review the full SBRI press release please click here

Dr David Parry, CEO, SEHTA says “We are delighted to be working with Beamline Diagnostics on their SBRI-funded project to develop further and commercialise their screening system for colon cancer.  It’s always a pleasure to work with innovative energetic companies like Beamline who are developing ground-breaking technologies in such important clinical areas”.

Dr Liberty Foreman, CEO & Co-Founder, Beamline Diagnostics says “We are really looking forward to working with SEHTA over the duration of the SBRI contract. I first met SEHTA at one of their events. After watching some of the other companies they support present I thought we would be able to work really well together.”

For more information about Beamline Diagnostics please visit www.beamlinediagnostics.com or contact Dr Liberty Foreman, CEO & Co-Founder, Beamline Diagnostics directly at l.foreman@beamlinediagnostics.com